CoChat

Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

Ingwersen, Steen H., Khurana, Manoj, Madabushi, Rajanikanth, Watson, Estelle, Jonker, Daniël M., Thi, Tu Duyen Le, Jacobsen, Lisbeth V., Tornøe, Christoffer W. · 2012 · The Journal of Clinical Pharmacology
Cited by 35

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide was approved in 2010 by the US Food and Drug Administration (FDA) as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This article provides insights into the use of pharmacometric analyses for regulatory review with a focus on the dosing recommendations. The assessment was based on the totality of exploratory and confirmatory analysis of dose‐finding and pivotal clinical data and was structured around a set of key questions in accordance with current FDA review practice. For the pharmacometric review of liraglutide, the key questions focused on exposure‐response relationships for effects on fasting plasma glucose, hemoglobin A 1c, and calcitonin and on variability in exposure across demographic subgroups of patients. The importance of conducting exploratory exposure‐response analysis and population pharmacokinetic studies in clinical drug development to support dosing recommendations is highlighted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270011430504

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 35

Metadata

Authors
Ingwersen, S. H., Khurana, M., Madabushi, R., Watson, E., Jonker, D. M., Thi, T. D. L., Jacobsen, L. V., & Tornøe, C. W.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2012-12
Volume
52
Issue
12
Pages
1815-1823
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2041395244
Cited by
35
References
6
FWCI
0.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment. https://app.cochat.ai/papers/10.1177/0091270011430504
The paper
Ingwersen, S. H., Khurana, M., Madabushi, R., Watson, E., Jonker, D. M., Thi, T. D. L., Jacobsen, L. V., & Tornøe, C. W. (2012). Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270011430504

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.